Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis
NCT05058417 · Sadat City University · PHASE2 · withdrawn · last registry update 2025-07-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Institutional and funding constrains” | – | Registry record, Sadat City University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC5A2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-13Results posted on the registry: Bayer, Finerenone (BAY94-8862 ) 10 mg + Empagliflozin (NCT05254002)
- 2026-07-06Phase 3 first posted: Beni-Suef University, Dapagliflozin (NCT07684326)
- 2026-06-30Also stopped (terminated): Washington University School of Medicine, Dapagliflozin (NCT04887935)
- 2026-06-26Results posted on the registry: AstraZeneca, Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg (NCT06350123)
- 2026-06-23Phase 3 first posted: AstraZeneca, Elecoglipron + Dapagliflozin (NCT07662109)
- 2026-06-23Phase 3 first posted: AstraZeneca, Elecoglipron + Placebo (NCT07662135)
- 2026-06-23Phase 3 first posted: AstraZeneca, Elecoglipron + Dapagliflozin (NCT07662044)
- 2026-06-18Also stopped (withdrawn): Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Empagliflozin (NCT05960617)
- 2026-06-16Results posted on the registry: The TIMI Study Group, Dapagliflozin + Placebo (NCT04363697)
- 2026-06-09Phase 3 first posted: Sun Yat-sen University, Group A (triple combination intensive therapy group) + Group B (standard therapy group) (NCT07635953)
- 2026-06-08Results posted on the registry: University Health Network, Toronto, Dapagliflozin 10 MG Oral Tablet + Placebo Matching Dapagliflozin Oral Tablet (NCT04965935)
- 2026-06-04Results posted on the registry: Stanford University, Ertugliflozin (NCT04167761)
- 2026-06-03Phase 3 first posted: AstraZeneca, Balcinrenone/dapagliflozin + Dapagliflozin (NCT07624305)
- 2026-05-20Phase 3 first posted: Chittagong Medical College, Dapagliflozin +Finerenone arm + Dapagliflozin arm (NCT07598864)
- 2026-05-15Phase 3 first posted: Ain Shams University, Empagliflozin (EMPA) (NCT07591077)
- 2026-05-14Phase 3 first posted: Dr Mudassar Saeed Pansota, ARBs alone + ARBs in combination of SGLT2i (NCT07586371)
- 2026-05-13Also stopped (terminated): Washington University School of Medicine, Carvedilol + Empagliflozin (NCT06844669)
- 2026-05-08Results posted on the registry: University of Chicago, SGLT2i (NCT05278962)
- 2026-05-06Phase 3 first posted: Washington University School of Medicine, HFrEF Polypill (NCT07569640)
- 2026-04-16Phase 3 first posted: King's College London, Empagliflozin 10mg OD (NCT07533747)
- 2026-04-16Also stopped (terminated): Department of Nephrology Clinic Ottakring Vienna, a drug against SLC5A2 (NCT06094231)
- 2026-04-15Results posted on the registry: Amsterdam UMC, location VUmc, Ertugliflozin 15 mg (NCT05727579)
- 2026-03-30Also stopped (terminated): The George Institute, Dapagliflozin 10mg Tab + Placebo (NCT05468203)
- 2026-03-23Phase 3 first posted: University Hospital, Strasbourg, France, Dapaglifozin + Placebo (NCT07488689)
- 2026-03-13Phase 3 first posted: Hospital de Clinicas de Porto Alegre, Furosemide 40 Milligrams. + Furosemide 40 Milligrams. (NCT07469722)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision